Akums Drugs IPO – Review, Bid, Size, Allotment, Subscription, GMP & RHP

Let’s have a detailed review of the company and analytics of the Akums Drugs and Pharmaceuticals IPO release date, IPO offer price, subscription, Akums Drugs and Pharmaceuticals Limited IPO allotment, grey market price, and other details like the company’s background, its financial positions, its promoters, and other related things.

Akums Drugs and Pharmaceuticals IPO is listed at a [●] premium. Check out the live share price by clicking on the below link.

Akums Drugs and Pharmaceuticals IPO – Summary

Established in 2004, they are a pharmaceutical contract development and manufacturing organization (“CDMO”) offering a comprehensive range of pharmaceutical products and services in India and overseas.

As one of the leading CDMOs in India, they own the intellectual property for the manufacturing processes of several of their formulations, and their core business is focused on providing end-to-end product development and manufacturing solutions to their clients. Some of their other services include formulation research and development (“R&D”), preparation and filing of regulatory dossiers in the Indian and global markets, and other testing services

The promoters of this company are SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST. The lead manager of the issue is ICICI Securities Limited, Axis Capital Limited, Citigroup Global Markets India Private Limited, and Ambit Private Limited, and the Registrar of this issue is Link Intime India Private Limited.

Akums Drugs and Pharmaceuticals IPO Date

The opening and closing dates of Akums Drugs and Pharmaceuticals IPO are July 30, 2024 and August 1, 2024, respectively.

Akums Drugs and Pharmaceuticals IPO Subscription

The shares subscribed by the public will be updated here.

Akums Drugs and Pharmaceuticals IPO Allotment Status

Here, you can find the Allotment Status of this IPO.

Allotment of Equity Shares pursuant to the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders pursuant to the Offer for Sale to the successful Bidders. However, the Allotment Status is not yet disclosed.

Akums Drugs and Pharmaceuticals Limited IPO Listing Date

Find the dates below on basis of allotment, refund, listing, and more:

Akums Drugs and Pharmaceuticals IPO Price Band

The face value of each share is Rs.10, but the price band of the IPO is Rs 646 to Rs 679 

Akums Drugs and Pharmaceuticals IPO Equity Size

This Initial Public Issue of 27,345,162 Equity Shares of Rs.10 each for cash at a price of Rs 646 to Rs 679 per equity share aggregating to 1,856.74 Cr.

Akums Drugs and Pharmaceuticals IPO Share Offering

Fresh Issue: The Issue (excluding the Market Maker Reservation Portion) of 10,014,727 Equity Shares of Rs.10/ each.

Issue Size: 27,345,162 Equity Shares of Rs.10 each, aggregating to 1,856.74 Cr.

Open Free Demat Account Now!

Akums Drugs and Pharmaceuticals IPO – Live Performance

The listing date of this IPO is August 6, 2024. You can check the live performance of the IPO here, only after it is listed on exchanges.

Akums Drugs and Pharmaceuticals IPO Grey Market Premium

The Akums Drugs and Pharmaceuticals Limited IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is Rs X. 

Akums Drugs and Pharmaceuticals IPO – Company Overview

They are the largest India-focused CDMO in terms of revenue, production capacity and clients served during the Financial Year 2023 (among CDMOs assessed by F&S). As a CDMO, they produce an extensive range of dosage forms including tablets, capsules, liquid orals, vials, ampoules, blow-filledseals, topical preparations, eye drops, dry powder injections, and gummies, among others.

During the Financial Year 2024, they had a market share of 30.2% of the Indian domestic CDMO market by value, which increased from 26.7% during the Financial Year 2021.

The Indian domestic CDMO market is forecasted to grow at a CAGR of 14.3% between Financial Year 2024 and Financial Year 2028, nearly doubling its historical growth rate. Moreover, the market size of Indian domestic CDMO market is forecasted to grow to USD 2.8 billion during Financial Year 2028

Akums Drugs and Pharmaceuticals IPO – Financial Statements

A quick look into the past financial performance of the company to understand its performance of the business and evaluate the growth prospectus:

Financial Summary:

Earnings per Equity Share (in Million)

Further, their PAT for the period ended on March 31, 2024, March 31, 2023, and March 31, 2022, were Rs. 7.90 Million, Rs. 978.17 Million and Rs. (2,508.74) Million respectively.

Akums Drugs and Pharmaceuticals IPO – Promoters

The Promoter of this company is:

• SANJEEV JAIN,
• SANDEEP JAIN
• AKUMS MASTER TRUST

List of Related Parties (Key Managerial Personnel)

• Sanjeev Jain, Managing Director
• Sandeep Jain, Managing Director
• Sanjay Sinha, Whole Time Director
• Sunil Kumar Thakur, Non-Executive Director, Nominee of Ruby QC Investment Holdings Pte. Ltd.

Akums Drugs and Pharmaceuticals IPO – Promoters Holding

• Pre-Issue Share Holding – 84.94%
• Post-Issue Share Holding – %

Akums Drugs and Pharmaceuticals IPO Offer Details or Issue Details

Akums Drugs and Pharmaceuticals IPO Issue Object

Their Company proposes to utilize the Net Proceeds towards funding the following objects:

1. Repayment/ prepayment of indebtedness of their Company;
2. Repayment/ prepayment of indebtedness of their Subsidiariesnamely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited;
3. Funding incremental working capital requirements of their Company;
4. Pursuing inorganic growth initiatives through acquisitions; and
5. General corporate purposes.

Akums Drugs and Pharmaceuticals IPO – Business Strategy

• Leverage their leadership position to continue to increase their market share and consolidate their position in the CDMO market
• Sustaining R&D for product development across therapies and dosage forms
• Grow their domestic formulations business
• Expanding their global presence through strategic initiatives
• Scale their API business

Akums Drugs and Pharmaceuticals IPO – Basis of Offer Price

The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.

Qualitative factors are:

• Largest India-focused CDMO serving the Indian domestic pharmaceutical industry;
• Diverse client base with longstanding CDMO relationships;
• Large and rapidly growing R&D capabilities across their product portfolio;
• Strategic presence across the pharmaceutical value chain; and
• Experienced and entrepreneurial management team with a proven track record and marquee healthcare-focused PE investor.

The relevant quantitative factors are:

Akums Drugs and Pharmaceuticals IPO: Competitive Peers

Akums Drugs and Pharmaceuticals IPO Lead Managers

Akums Drugs and Pharmaceuticals IPO Registrar to offer

Akums Drugs and Pharmaceuticals IPO – Other Details

• Statutory Auditor – Walker Chandiok & Co LLP, Chartered Accountants
• Legal Counsel to the Company – Cyril Amarchand Mangaldas
• Bankers to the Company – Citibank, HSBC Limited, HDFC Bank, and Yes Bank Limited

Akums Drugs and Pharmaceuticals IPO Review by Stock Brokers

Subscribe to Akums Drugs and Pharmaceuticals IPO

Akums Drugs and Pharmaceuticals Limited IPO News

News 1 – IPO DRHP Download

News 2 – IPO RHP Prospectus Download

Akums Drugs and Pharmaceuticals IPO Review FAQs

Check out various FAQs related to Akums Drugs and Pharmaceuticals IPO:

What is the Issue Size of Akums Drugs and Pharmaceuticals IPO?

The Company is making an initial public offer of 27,345,162 equity shares. They vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.

What is the Price band of Akums Drugs and Pharmaceuticals IPO?

The price band for this particular IPO ranges between Rs 646 to Rs 679. As far as the face value of the share is concerned, it is Rs. 2 per share.

What is the Akums Drugs and Pharmaceuticals IPO Open Date?

The opening and closing dates for this IPO have been updated. The IPO is set to open on July 30, 2024, while the closing date is set at August 1, 2024.

What is the Akums Drugs and Pharmaceuticals IPO Allotment Date?

They also have the news regarding the respective allotment dates of this IPO. The basis of Allotment finalization is on August 2, 2024, refund initiation is on August 5, 2024, credit of shares is on August 5, 2024, and share listing date is on August 6, 2024.

What is the Akums Drugs and Pharmaceuticals IPO Listing Date?

Shares of this company shall be listed in the exchanges on August 6, 2024. The date, when the listing would be done, is stagnant on August 6, 2024.

Who is the Registrar of Akums Drugs and Pharmaceuticals IPO?

One of the reputed registrars is managing the issue of this IPO, i.e. Link Intime India Private Limited. Their website will help you regarding the further information you are on the lookout for.

Who is the Promoter of Akums Drugs and Pharmaceuticals IPO?

Here are the promoters of this IPO – SANJEEV JAIN, SANDEEP JAIN AND AKUMS MASTER TRUST. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.

What is the GMP of Akums Drugs and Pharmaceuticals IPO?

They have obtained the GMP of this IPO and it is Rs NA. Further insights into the Kostak rate and subject to sauda or SS are as well included in this report.

Is Akums Drugs and Pharmaceuticals IPO Good for Investment?

They have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.

What is the PAT of Akums Drugs and Pharmaceuticals Company?

They have the information on company financials, and according to that, they have the figures from the last few years to provide. PAT for the financial year 2024 in Million is 7.90, 2023 is 978.17, and 2022 is (2,508.74).

Featured Topics